{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:50:11Z","timestamp":1789617011288,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder that may progress to kidney failure, accounting for 5\u201310% of all patients with end-stage kidney disease (ESKD). Clinical data, as well as molecular genetics and advanced imaging techniques have provided surrogate prognostic biomarkers to predict rapid decline in kidney function, nonetheless enhanced tools for assessing prognosis for ADPKD are still\u00a0needed. The aim of this study was to analyze specific microRNAs involved in the pathogenesis of ADPKD and in the development of renal fibrosis, evaluating their potential role as predictors of renal function loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated kidney function by estimated glomerular filtration rate (eGFR) in 32 ADPKD patients in different stages of kidney disease at T0 and after a 24-month follow up (T1). Patients were divided into two groups: Rapid disease progression ([RP], n 15) and Non-rapid disease progression ([NRP], n 17), according to the Mayo Clinic classification criteria. At T0, ADPKD patients underwent plasma sampling for quantitative analysis of h-miR-17-5p, h-miR-21-5p and h-miR-199a-5p microRNA expression, using the quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) method and a 3\u00a0T magnetic resonance imaging (MRI), using an advanced MRI imaging protocol, for the quantification of total kidney volume (TKV), total perfusion volume (TPV) and total fibrotic volume (TFV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The expression of h-miR17-5p was higher (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) in ADPKD patients with rapid disease progression. h-miR-17-5p, h-miR-21-5p and h-mir-199-5p showed a positive and significant correlation with the eGFR slope (mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) but not with the eGFR at both T0 and T1. Both total fibrotic volume (cm\n                      <jats:sup>3<\/jats:sup>\n                      ) and height-adjusted total fibrotic volume (cm\n                      <jats:sup>3<\/jats:sup>\n                      \/m) were positively and significantly correlated to h-miR 21-5p and h-miR 199-5p (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), but not to total kidney volume (cm\n                      <jats:sup>3<\/jats:sup>\n                      ) and height-adjusted total kidney volume (cm\n                      <jats:sup>3<\/jats:sup>\n                      \/m).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The microRNAs we studied were associated with fibrosis and renal damage, suggesting their possible role as biomarkers able to identify ADPKD patients at high risk of disease progression regardless of the degree of kidney function, and therefore suitable for medical therapy, and may help uncovering new molecular mechanisms underlying cystogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-01965-0","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T15:01:49Z","timestamp":1720191709000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-2954","authenticated-orcid":false,"given":"Silvia","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Mastroluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo Marco","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Muscaritoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lucciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Felli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silverio","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Tartaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesarina","family":"Ramaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"De Intinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"1965_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287\u20131301","journal-title":"Lancet"},{"key":"1965_CR2","first-page":"2143","volume":"18","author":"S Rossetti","year":"2007","unstructured":"Rossetti S, Consugar MB, Chapman AB et al (2007) Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am SocNephrol 18:2143\u20132160","journal-title":"J Am SocNephrol"},{"issue":"1","key":"1965_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres VE, Harris PC (2014) Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25(1):18\u201332","journal-title":"J Am Soc Nephrol"},{"key":"1965_CR4","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/j.1523-1755.2005.00203.x","volume":"67","author":"PR Fain","year":"2005","unstructured":"Fain PR et al (2005) Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 67:1256\u20131267","journal-title":"Kidney Int"},{"key":"1965_CR5","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1172\/JCI64313","volume":"122","author":"K Hopp","year":"2012","unstructured":"Hopp K et al (2012) Functional polycystin-1 dosage govern: autosomal dominant polycystic kidney disease severity. J Clin Invest 122:4257\u20134273","journal-title":"J Clin Invest"},{"key":"1965_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E et al (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006\u20131013","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1965_CR7","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/gft521","volume":"29","author":"I Rowe","year":"2014","unstructured":"Rowe I, Boletta A (2014) Defective metabolism in polycystic kidney disease: potential for therapy and open questions. Nephrol Dial Transplant 29(8):1480\u20131486","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1965_CR8","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220126","volume":"43","author":"D Odedra","year":"2023","unstructured":"Odedra D, Sabongui S, Khalili K, Schieda N, Pei Y, Krishna S (2023) Autosomal dominant polycystic kidney disease: role of imaging in diagnosis and management. Radiographics 43(1):e220126","journal-title":"Radiographics"},{"issue":"4","key":"1965_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2215\/CJN.02251205","volume":"1","author":"L Antiga","year":"2006","unstructured":"Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, Remuzzi G, Remuzzi A (2006) Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 1(4):754\u2013760","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1965_CR10","first-page":"1291","volume":"1812","author":"WDP Cyclic","year":"2011","unstructured":"Cyclic WDP (2011) Cyclic AMP-mediated cyst expansion. Biochem Biophys Acta 1812(10):1291\u20131300","journal-title":"Biochem Biophys Acta"},{"issue":"3","key":"1965_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","volume":"64","author":"AB Chapman","year":"2003","unstructured":"Chapman AB, Guay-Woodford LM, Grantham JJ et al (2003) Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64(3):1035\u20131045","journal-title":"Kidney Int"},{"issue":"1","key":"1965_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV et al (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26(1):160\u2013172","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1965_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/imj.14039","volume":"48","author":"S Lai","year":"2018","unstructured":"Lai S, Mastroluca D, Letizia C, Petramala L, Perrotta AM, DiGaeta A, Ferrigno L, Ciccariello M, D\u2019Angelo AR, Panebianco V (2018) Magnetic resonance imaging 3T and total fibrotic volume in autosomal dominant polycystic kidney disease. Intern Med J 48(12):1505\u20131513. https:\/\/doi.org\/10.1111\/imj.14039. (PMID: 30043487)","journal-title":"Intern Med J"},{"issue":"12","key":"1965_CR14","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s11255-023-03551-y","volume":"55","author":"S Lai","year":"2023","unstructured":"Lai S, Perrotta AM, Panebianco V, Mazzaferro S, Men\u00e8 P, Pellicano C, Tinti F, Muscaritoli M, Cianci R, Gigante A (2023) Parasympathetic activity and total fibrotic kidney in autosomal-dominant polycystic kidney disease patients: a pilot study. Int Urol Nephrol 55(12):3153\u20133158. https:\/\/doi.org\/10.1007\/s11255-023-03551-y. (Epub 2023 Apr 12. PMID: 37043156; PMCID: PMC10611859)","journal-title":"Int Urol Nephrol"},{"key":"1965_CR15","first-page":"64","volume":"455","author":"D Baek","year":"2008","unstructured":"Baek D, Vill\u00e9n J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nat Cell Biol 455:64\u201371","journal-title":"Nat Cell Biol"},{"key":"1965_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12:861\u2013874","journal-title":"Nat Rev Genet"},{"issue":"6","key":"1965_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1440-1797.2010.01363.x","volume":"15","author":"JY Li","year":"2010","unstructured":"Li JY, Yong TY, Michael MZ, Gleadle JM (2010) Review: the role of microRNAs in kidney disease. Rev Nephrol (Carlton) 15(6):599\u2013608","journal-title":"Rev Nephrol (Carlton)"},{"issue":"1","key":"1965_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D (2009) Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20(1):205\u2013212","journal-title":"J Am Soc Nephrol"},{"key":"1965_CR19","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/j.1523-1755.2004.66003.x","volume":"66","author":"A Persu","year":"2004","unstructured":"Persu A et al (2004) Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 66:2132\u20132136","journal-title":"Kidney Int"},{"issue":"9","key":"1965_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/1471-2164-9-624","volume":"23","author":"P Pandey","year":"2008","unstructured":"Pandey P, Brors B, Srivastava PK, Bott A, Boehn SNE, Groene H-J, Gretz N (2008) Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 23(9):624","journal-title":"BMC Genomics"},{"issue":"6","key":"1965_CR21","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.3390\/ijms22063014","volume":"22","author":"JX Zhou","year":"2021","unstructured":"Zhou JX, Li X (2021) Non-coding RNAs in hereditary kidney disorders. Review Int J Mol Sci. 22(6):3014","journal-title":"Review Int J Mol Sci."},{"issue":"21","key":"1965_CR22","first-page":"195","volume":"15","author":"L Sun","year":"2015","unstructured":"Sun L, Zhu J, Ming Wu, Sun H, Zhou C, Lili Fu, Chenggang Xu, Mei C (2015) Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C. Med Sci Monit 15(21):195\u2013200","journal-title":"Med Sci Monit"},{"issue":"8","key":"1965_CR23","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1681\/ASN.2015060634","volume":"27","author":"R Lakhia","year":"2016","unstructured":"Lakhia R, Hajarnis S, Williams D, Aboudehen K, Yheskel M, Xing III C, Hatley ME, Torres VE, Wallace DP, Patel V (2016) MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease. J Am Soc Nephrol 27(8):2319\u20132330","journal-title":"J Am Soc Nephrol"},{"key":"1965_CR24","doi-asserted-by":"publisher","first-page":"14395","DOI":"10.1038\/ncomms14395","volume":"8","author":"S Hajarnis","year":"2017","unstructured":"Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Aboudehen K, Zhang S, Kersjes K, Galasso R, Li J, Kaimal V, Lockton S, Davis S, Flaten A, Johnson JA, Holland WL, Kusminski CM, Scherer PE, Harris PC, Trudel M, Wallace DP, Igarashi P, Lee EC, Androsavich JR, Patel V (2017) MicroRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun 8:14395","journal-title":"Nat Commun"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01965-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-01965-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01965-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:00Z","timestamp":1777564380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/1\/153\/8304313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["1965"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-01965-0","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was in accordance with the ethical standards of the Local Clinical Research Ethics Committee where the studies were conducted (IRB approval number 3169\/15) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable in this section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}